Please visit answersincme.com/VTG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lupus nephritis (LN) discusses the latest evidence and guidance on using biologic therapies in this patient population. Upon completion of this activity, participants should be better able to: Discuss the rationale for adding a biologic agent to standard immunosuppressive therapy to improve outcomes in LN; Review the clinical evidence for available and emerging B-cell biologic agents in LN; and Identify patients with LN who are candidates to receive biologic add-on therapy.